ACET Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -0.02%, SMA50 -13.11%, SMA200 -27.6%). The stock’s 14-day RSI is 43.69 (neutral), while the ATR of 0.65 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -53.96% below its high and over 12.25% above its low. Average 10-day trading volume of 268.57 thousand shares is below the 3-month average of 2.09 million, indicating normal recent market interest.

Adicet Bio, Inc. has 153.26 million shares outstanding. The public float is 8.41 million shares, elevated short interest at 0.72% of float. This equals 931.91 thousand shares. The short ratio is 6.16 days. Institutional investors hold 36.9% of the float. Insiders own 1.46%. SILVERSTEIN JONATHAN holds 4.83 million shares, ORBIMED ADVISORS LLC has 4.49 million shares and Sinclair Andrew has 2.14 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Adicet Bio, Inc. generated EPS of -$20.22 over the past year. Five-year average earnings growth is 36.74%. Wall Street analysts project EPS growth of 21.58% annually over the next five years. The latest quarter delivered EPS of -$0.29. The next quarter is forecast at -$2.77. Next year's EPS is expected at $18.41. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $128.00 to $4.00. The high target offers 1494.02% upside. The low target suggests -50.19% downside. The mean target is $27.17. This offers 238.36% upside. Adicet Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by 11.54%. The prior quarter beat by 6.25%. Over the last six quarters, Apple has recorded several small beats. These include -5.71% in August 13, 2024.

Adicet Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $7.15. This means the shares are trading above this model’s fair value.

Adicet Bio, Inc. (NASDAQ:ACET) closed at $8.03 USD, losing -$0.06 (-0.74%) from the previous close of $8.09. The stock is currently mid-range between its 52-week high and low $7.15 and $17.44. With a market capitalization of about $76.92 million, Adicet Bio, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.61). Key stats such as the average daily volume over the past year has been around 163.60 thousand shares, in line with its 52-week average. Headquartered in Boston, MA, Adicet Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Chen Schor, the company employs approximately 152 people and listed since January 26, 2018. Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases.

Adicet Bio, Inc. trades at a P/E ratio of -0.4, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.42 suggesting the stock is closer to book value. The P/FCF stands at -0.77, also below market averages.

Our AI price prediction model suggests that Adicet Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 23.91%, with price expected at $9.95 by January 23, 2026, within a range of $7.17 to $12.51 3-Month Outlook: Projected rise of 138.98%, reaching $19.19 by April 09, 2026, with a range of $19.11 to $19.41. 1-Year Outlook: Projected gain of 201.49%, with price at $24.21 by December 31, 2026, within a range of $0.00 to $0.00.

Adicet Bio, Inc. (NASDAQ:ACET) shares are flat -3.92% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Adicet Bio, Inc. trading at a premium to the broader market with a P/E of -0.4. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $23.00, suggesting 186.43% upside. Our AI forecast model points to short-term strength (23.91% over two weeks), a medium-term rise (138.98% over three months), and a longer-term gain (201.49% over one year), with expected trading ranges indicating moderate volatility.